DMD and Duchenne muscular dystrophy: In the primary report of a phase 1b trial, adeno-associated virus gene therapy with fordadistrogene movaparvovec in patients with Duchenne muscular dystrophy was well tolerated in an ambulatory cohort, and mini-dystrophin expression was increased in the high-dose cohort.